



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Temporary Member’s Name: Dr. James Hildreth

Committee: Vaccines and Related Products Advisory Committee (VRBPAC)

Meeting Date: September 17, 2021

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the meeting topic: The Committee will meet in open session to discuss Pfizer-BioNTech’s supplemental Biologics License Application for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, Comirnaty, in individuals 16 years of age and older, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
Clinical Trial Participation	Affected Firm	\$0 - \$5,000
<b>II. Other Imputed Interests</b>		
Vaccine Test Site; Meharry Medical College	(b) (4) and NIH/NIAID, Affected Firms	\$1,500,000 - \$2,000,000
Vaccine Test Site; Meharry Medical College	(b) (4) Affected Firm	\$400,000 - \$600,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_9-10-2021\_\_\_\_\_  
Date

James Hildreth, M.D., Ph.D.